Premium
Vasculitic leg ulcers in a patient with mixed myelodysplastic and myeloproliferative syndrome
Author(s) -
Hoetzenecker W,
Zipfel M,
Guenova E,
Hoetzenecker K,
Röcken M
Publication year - 2008
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2007.02271.x
Subject(s) - medicine , dermatology , university hospital , surgery
1 Jacobi A, Mahler V, Schuler G, Hertl M. Treatment of inflammatory dermatoses by tumor necrosis factor antagonists. J Eur Acad Dermatol Venereol 2006; 20: 1171– 1187. 2 Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876–885. 3 Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn’s disease. Inflamm Bowel Dis 2001; 7: 38–42. 4 Ferkolj I, Ihan A, Markovic S, Veceric Z, Pohar M. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn’s disease. J Gastrointestin Liver Dis 2006; 15: 231–235. 5 Meijer MJ, Mieremet-Ooms MA, van Duijn W et al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 200–210. 6 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006; 9: 221–233.